Catalyst

Slingshot members are tracking this event:

Catalyst Therapeutics (CRPX) announces topline data from Phase 2/3 trial evaluating Firdapse in treating for patients with MuSK-MG myasthenia gravis

Source Link:
http://seekingalpha.com/article/4055760-catalyst-pharmaceutical-partners-cprx-ceo-pat-mcenany-q4-2016-results-earnings-call?page=2

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
CPRX Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Mar 15, 2017
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Musk-mg, Firdapse, Phase 2/3
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.